CHICAGO -- Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received ...

SAN ANTONIO — Fam-trastuzumab deruxtecan-nxki improved outcomes compared with capecitabine-based regimens as third-line treatment for certain patients with HER2-positive metastatic breast cancer ...

Patients were randomly assigned in a 2:1 ratio to receive trastuzumab deruxtecan or the physician’s choice of chemotherapy. The primary end point was progression-free survival in the hormone ...

Trastuzumab deruxtecan-THP was associated with a statistically significant and clinically meaningful improvement in pathologic complete response rate vs standard of care. The DESTINY-Breast11 ...

SAN ANTONIO — Fam-trastuzumab deruxtecan-nxki significantly extended OS compared with ado-trastuzumab emtansine among previously treated patients with HER2-positive unresectable or metastatic ...

Patients treated with trastuzumab deruxtecan + pertuzumab had a statistically significant and clinically meaningful improvement in PFS compared with standard of care. Topline results were ...

In the HER2-low population, treatment with trastuzumab deruxtecan reduced the risk of disease progression or death by 38% compared with chemotherapy. The Food and Drug Administration (FDA ...

Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...

A study demonstrated the efficacy of trastuzumab deruxtecan (Enhertu) in patients with HER2-positive advanced or metastatic breast cancer, including those with brain metastases. Senior author ...

So, it assumed the proportion of people having subsequent treatments to be 66.7% in both the trastuzumab deruxtecan and trastuzumab emtansine arms, based on clinical expert opinion. In response to ...

COP, cryptogenic organizing pneumonia; CT, computed tomography; GGO, ground-glass opacities; T-DXd, trastuzumab deruxtecan. Fig 2. COP pattern of pneumonitis in a 76-year-old woman with breast cancer ...

The safety profile of the novel antibody-drug conjugate was "manageable" and comparable to that of a similar drug, trastuzumab deruxtecan, researchers said. If approved, trastuzumab rezetecan ...